PDF file - 316K, Supplementary Fig. S1: Effective depletion of PDCA-1+ cells in mouse splenocytes. Supplementary Fig. S2: Validation of gene expression by quantitative real-time PCR. Supplementary Fig. S3: Effects of TLR ligands on body weight changes in mice treated with subcutaneous injections of LLC/SeV/GM cells. Supplementary Fig. S4: Increased number of TVS-infiltrating PDCA-1+ cells in mice treated with combined irLLC/SeV/GM cells and imiquimod. Supplementary Fig. S5: Increased serum IFN-a level in mice treated with combined irLLC/SeV/GM cells and imiquimod. Supplementary Fig. S6: Prophylactic tumor vaccination using irLLC/SeV/GM cells induced significant antitumor effects in a syngeneic mouse model. Supplementary Fig. S7: Enhanced expression levels of maturation and costimulatory molecules including CCR7, CD40, MHC class I, and MHC class II in tumor cells-derived GM-CSF-sensitized DCs in TDLNs.